Can Some HER2-Positive Breast Cancer Patients Avoid Surgery?
Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.
In this study we designed a probemix to detect the amplification of the four HER oncogenes in a single reaction. In addition, we developed a protocol based on the combination of MLPA with ddPCR to detect the tumor proportion of co-amplified HERs. On 111 IDC, the HER2 MLPA results were validated by FISH (Adjusted r 2 = 0,91, p
Authors: Wysocka J, Adamczyk A, Kruczak A, Niemiec J, Sas-Korczyńska B Abstract Apocrine carcinoma is a very rare type of breast cancer, which represents 0.5-4% of all breast cancers. The aim of the study was to analyze biological and clinical features of apocrine carcinoma and their influence on patients survival. The studied group consists of 57 patients, who underwent treatment between 1987 and 2010. Expression of ER, PgR, HER2, AR, GCDFP-15, EGFR, CK 5/6, CK 8/18 and Ki-67 was assessed immunohistochemically on formalin-fixed paraffin-embedded tissue sections. Presen...
CONCLUSIONS: When conception occurs inadvertently during assumption of tamoxifen or anti-HER2 agents, their effects on the fetus and on the course of pregnancy are not completely understood. Further studies are needed in this setting, highlighting the importance to share clinical experiences. PMID: 32729389 [PubMed - as supplied by publisher]
CONCLUSION: The introduction of MGAs in the clinical evaluation of patients with luminal eBC with intermediate risk is economically sustainable and contributes towards preserving quality of life of eligible women. PMID: 32729378 [PubMed - as supplied by publisher]
In conclusion,our findings suggest that pyrotinib could restore sensitivity of 5-FU-resistant HER2+breast cancer cells to 5-FU through downregulating the expression levels of TS andABCG2. PMID: 32727638 [PubMed - as supplied by publisher]
Condition: Advanced or Metastatic Breast Cancer Interventions: Drug: Trastuzumab deruxtecan; Drug: Capecitabine; Drug: Paclitaxel; Drug: Nab-Paclitaxel Sponsors: AstraZeneca; Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo Not yet recruiting
Background: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown.Patients and Methods: Consecutive breast cancer patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital between January 2009 and December 2018 were retrospectively analyzed. Patients with available 21-gene RS result for the primary tumor and reporting disease recurrence during follow-up were included. Associa...
Cancer cell invasion and metastasis rely on invadopodia, important extensions of the cytoskeleton that initiate degradation of the basement membrane that holds a cell in place. Transforming growth factor-β (TGF-β) is well-known to induce breast cancer migration and invasion, but the mechanism by which TGF-β signaling converts into cell motility is not completely understood. A study from Kiepas et al. revealed a new TGF-β–dependent role for Src homology/collagen adaptor protein (SHCA) in the initiation of dynamic adhesion complexes involved in the formation of invadopodia. These results highlight n...
Future Oncology, Ahead of Print.
(Duke University Medical Center) A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research.